Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.

Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.

http://www.wikidata.org/entity/Q34422585

about

RB1: a prototype tumor suppressor and an enigma Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Management of retinoblastoma in children: current status.Advances in the use of prodrugs for drug delivery to the eye.Syk inhibitors in clinical development for hematological malignancies.RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development.Retinoblastoma

P2860

Q26866393-0E9FEB5D-DFE4-4AE5-A15D-3559FDE2731D Q35706804-A676ACDF-3AD2-4BDA-B641-BFD56A1FCFA7 Q38368017-D55F1AD0-6CB5-428B-97C1-E67C03B6CD09 Q38904119-FB09342A-33F5-47D2-B34F-C32458A0875B Q42011012-57E1AEA0-63EC-4F2E-8480-A1F49291DE75 Q55102301-A0D4E3D2-7A05-4B42-89C8-69A94DBA871F Q58347703-3BCAD20A-CA07-47B2-BB91-4B8F05C66565

P2860

Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.

http://www.wikidata.org/entity/Q34422585

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@ast

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@en

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@nl

type

label

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@ast

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@en

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@nl

prefLabel

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@ast

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@en

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@nl

P1433

Q34422585-8D742905-FA4A-49A3-B6D3-2437B0185073

P1476

Q34422585-F001F9B3-B122-404F-8761-A71A6AC02A8B

P2093

Q34422585-0FDC9053-A98F-466C-AA28-C01239F4ABA4

Q34422585-12E74765-B612-42C0-84FA-9E290A2EE861

Q34422585-1BAED623-780D-4A85-998A-04C4D466859B

Q34422585-49045B94-E2DD-4E88-8A2F-E4EC8D2B23EA

Q34422585-62E2CE97-6348-40B5-9BCA-7810A808CB59

Q34422585-8D17CFD8-B049-4242-91FB-5E8EF7EBDDF7

Q34422585-A614F14B-460B-4B9A-B5D6-7E0516172240

Q34422585-CB9FD8B5-6FCF-4155-A1B7-0934B879F812

Q34422585-EF308FE3-C8DE-487A-B549-C846C72B279C

Q34422585-F5DA8282-7D67-409E-8EF2-2D19BE54A568

P2860

Q34422585-009185B6-A84E-476D-AC84-91C5087243C2

Q34422585-02175F62-EDC2-4C59-8910-32D0ACEB26A5

Q34422585-07FC2FCE-1945-49A3-8978-59B5C67BC31E

Q34422585-0E7DD80C-41DD-43A3-9646-E3BFF4B3C9A7

Q34422585-1431E5C6-217E-4025-B3EA-CC90D9044436

Q34422585-1664A470-D464-41DD-86AC-05268A2B1D05

Q34422585-1C6CC57F-E826-42A3-B7FA-0CE024F11399

Q34422585-1F6FB8D4-AA33-4CBE-ADC6-1C5E54646D8D

Q34422585-296D56AF-73F6-4EC1-B9F7-004572ECCB30

Q34422585-305CD9BB-B0AE-40DD-A7C4-3653A5E3358D

P304

Q34422585-061B8A13-CDB7-4671-BEE5-3934EF72F952

P31

Q34422585-488C1B3B-2F24-42CA-B0FD-CAE5A89973F2

P356

Q34422585-B8229FA7-9F1E-4B9B-A009-C943B33146A6

P433

Q34422585-06903144-FFFC-4362-B906-6F29F080C17B

P478

Q34422585-F7838EDF-3DFC-48C9-85A5-919ACFA98493

P50

Q34422585-979692F8-F8D4-48F1-9B93-31E76F03A610

P577

Q34422585-6CA2E5B2-1B00-411C-9CCA-EE9D30AFACEA

P5875

Q34422585-70461310-7BA8-4457-8761-538DA888794C

P698

Q34422585-B9760DEF-0DA6-4894-AB82-6AE38E997B52

P921

Q34422585-62760369-1D1F-4D66-AF70-C2FDA6C2C932

P932

Q34422585-A802D3C5-F9D7-48A0-AFA5-06E3582E22DF

P356

S11095-014-1399-Y

P1433

Pharmaceutical Research

P1476

Pharmacokinetics and efficacy ...... r delivery for retinoblastoma.

@en

P2093

Burgess B Freeman

http://www.w3.org/2001/XMLSchema#string

Cori Bradley

http://www.w3.org/2001/XMLSchema#string

Eleanor M Pritchard

http://www.w3.org/2001/XMLSchema#string

Elizabeth Stewart

http://www.w3.org/2001/XMLSchema#string

Fangyi Zhu

http://www.w3.org/2001/XMLSchema#string

Jiakun Zhang

http://www.w3.org/2001/XMLSchema#string

Lei Yang

http://www.w3.org/2001/XMLSchema#string

Lyra Griffiths

http://www.w3.org/2001/XMLSchema#string

Michael A Dyer

http://www.w3.org/2001/XMLSchema#string

Praveen Kumar Suryadevara

http://www.w3.org/2001/XMLSchema#string

P2860

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Drug delivery for posterior segment eye disease.

Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

Diagnosis and management of retinoblastoma.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Mortality from second tumors among long-term survivors of retinoblastoma.

Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

P304

3060-3072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-014-1399-Y

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262929956

http://www.w3.org/2001/XMLSchema#string

P698

24906597

http://www.w3.org/2001/XMLSchema#string

P921

P932

4213378

http://www.w3.org/2001/XMLSchema#string